Generate Biomedicines Statistics
Total Valuation
GENB has a market cap or net worth of $1.74 billion. The enterprise value is $1.29 billion.
| Market Cap | 1.74B |
| Enterprise Value | 1.29B |
Important Dates
The next estimated earnings date is Monday, August 3, 2026, after market close.
| Earnings Date | Aug 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GENB has 128.19 million shares outstanding.
| Current Share Class | 128.19M |
| Shares Outstanding | 128.19M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +97.83% |
| Owned by Insiders (%) | 4.08% |
| Owned by Institutions (%) | 24.36% |
| Float | 60.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 57.37 |
| Forward PS | 82.38 |
| PB Ratio | 3.38 |
| P/TBV Ratio | 3.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 42.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.17, with a Debt / Equity ratio of 0.13.
| Current Ratio | 9.17 |
| Quick Ratio | 8.85 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -264.23 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -44.24% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $97,112 |
| Profits Per Employee | -$850,772 |
| Employee Count | 312 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GENB has paid $135,000 in taxes.
| Income Tax | 135,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 14.44 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 39.59 |
| Average Volume (20 Days) | 1,075,173 |
Short Selling Information
The latest short interest is 5.92 million, so 4.62% of the outstanding shares have been sold short.
| Short Interest | 5.92M |
| Short Previous Month | 4.55M |
| Short % of Shares Out | 4.62% |
| Short % of Float | 9.81% |
| Short Ratio (days to cover) | 4.93 |
Income Statement
In the last 12 months, GENB had revenue of $30.30 million and -$265.44 million in losses. Loss per share was -$4.57.
| Revenue | 30.30M |
| Gross Profit | -205.39M |
| Operating Income | -251.02M |
| Pretax Income | -240.23M |
| Net Income | -265.44M |
| EBITDA | -238.09M |
| EBIT | -251.02M |
| Loss Per Share | -$4.57 |
Balance Sheet
The company has $516.64 million in cash and $65.57 million in debt, with a net cash position of $451.07 million or $3.52 per share.
| Cash & Cash Equivalents | 516.64M |
| Total Debt | 65.57M |
| Net Cash | 451.07M |
| Net Cash Per Share | $3.52 |
| Equity (Book Value) | 514.80M |
| Book Value Per Share | 4.02 |
| Working Capital | 477.00M |
Cash Flow
In the last 12 months, operating cash flow was -$227.83 million and capital expenditures -$6.54 million, giving a free cash flow of -$234.38 million.
| Operating Cash Flow | -227.83M |
| Capital Expenditures | -6.54M |
| Depreciation & Amortization | 12.94M |
| Net Borrowing | -6.63M |
| Free Cash Flow | -234.38M |
| FCF Per Share | -$1.83 |
Margins
| Gross Margin | n/a |
| Operating Margin | -828.49% |
| Pretax Margin | -792.86% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GENB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -15.27% |
| FCF Yield | -13.48% |
Analyst Forecast
The average price target for GENB is $25.40, which is 87.32% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $25.40 |
| Price Target Difference | 87.32% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 42.47% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GENB has an Altman Z-Score of 6.41 and a Piotroski F-Score of 1.
| Altman Z-Score | 6.41 |
| Piotroski F-Score | 1 |